Impact of tocilizumab administration on mortality in severe COVID-19

Andrew Tsai, Oumou Diawara, Ronald G. Nahass, Luigi Brunetti
doi: https://doi.org/10.1101/2020.07.30.20114959

Article Information

doi 
https://doi.org/10.1101/2020.07.30.20114959
History 
  • August 2, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Andrew Tsai, PharmD1,
  2. Oumou Diawara, PharmD1,
  3. Ronald G. Nahass, MD1,2 and
  4. Luigi Brunetti, PharmD1,3,4,*
  1. 1Robert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA
  2. 2IDCare, 105 Raider Blvd, Hillsborough, NJ 08844, USA
  3. 3Ernest Mario School of Pharmacy, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
  4. 4Center of Excellence in Pharmaceutical Translational Research and Education, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
  1. ↵*Corresponding Author: Luigi Brunetti, PharmD, Associate Professor of Pharmacy, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, Tel. 908-595-2645, Email. brunetti{at}pharmacy.rutgers.edu
Back to top
Posted August 02, 2020.
Download PDF
Data/Code
Email
Impact of tocilizumab administration on mortality in severe COVID-19
Andrew Tsai, Oumou Diawara, Ronald G. Nahass, Luigi Brunetti
medRxiv 2020.07.30.20114959; doi: https://doi.org/10.1101/2020.07.30.20114959
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area